AIDS Healthcare Foundation (AHF) has criticized HIV drugmaker Gilead Sciences for pulling funding from AHF’s global programs, allegedly in response to AHF’s advocacy efforts that challenge Gilead, according to an AHF statement. For the past year, the nonprofit has publicly challenged Gilead on its drug pricing policies and its push to seek U.S. Food and Drug Administration (FDA) approval to sell its HIV med Truvada as a prevention pill, or pre-exposure prophylaxis (PrEP). AHF was told by a company representative recently that it will not be receiving Gilead funding support this year.

To read the AHF statement, click here.